Digital thErapy For Improved tiNnitus carE Study (DEFINE): Protocol for a Randomised Controlled Trial

Matthew E Smith; Dhiraj Sharma; Oliver Rivero-Arias; Kim Rand; Lucy Barrack; Emma Ogburn; Michael Young; Polly Field; Jan Multmeier; Jameel Muzaffar

doi:10.1101/2023.09.25.23296108

Abstract

Tinnitus is a common health condition, affecting approximately 15% of the UK population. The tinnitus treatment with the strongest evidence base is Cognitive Behavioural Therapy (CBT), with standard tinnitus therapy typically augmented with education, relaxation and other techniques. Availability of CBT and conventional tinnitus therapy more broadly is limited for tinnitus sufferers.

The DEFINE trial aims to assess whether smartphone-delivered tinnitus therapy, the Oto app, is as effective as current standard care, one-to-one therapist-delivered tinnitus treatment for the treatment of tinnitus in adults. The trial is registered in the ISRCTN Registry: ISRCTN99577932.

DEFINE is an open-label, non-inferiority, prospective, parallel design, randomised-controlled trial. Recruitment, interventions and assessments will be remote, enabling UK-wide participant involvement.

198 participants aged 18 years or more will be recruited via social media advertisement or via primary care physicians. A screening process will identify those with tinnitus that impacts health-related quality of life, and following consent smartphone-based audiometry will be performed. Randomisation 1:1 to the Oto app or one-to-one therapist-led tinnitus therapy will be performed centrally by computer, matching groups for age, sex and hearing level. Following participant allocation, the Oto app will be provided for immediate use, or a one-to-one remote therapy appointment booked to occur within approximately 1 week, with up to 6 sessions delivered.

Participant outcomes will be collected at 4,12, 26 and 52 weeks via questionnaire and phone call. The primary outcome is the change in Tinnitus Functional Index (TFI) total score measured at 26 weeks following allocation. Adverse events will be recorded. A health economic evaluation in the form of a cost-utility analysis will be performed using data from participant submitted EuroQol 5D-5L and Health Utilities Index Mark 3 scores and resource use data.

Trial results will be made publicly available, including a plain English summary.

Competing Interest Statement

MS (Chief Investigator), OR-A, KR, LB, MY, EG and JMul have no competing interests OR-A and KR are employees at Maths in Health BV PF is an employee of Oxford Pharmagenesis Ltd DS is the Founder's Associate at Oto Health Ltd JMuz is Chief Scientific Officer for Oto Health Ltd DS and JM have financial interests in Oto Health Ltd

Clinical Trial

ISRCTN99577932

Funding Statement

MS, JMuz, MY: INNOVATE UK Smart Grant 10062270

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

UK Health Research Authority (West-Midlands committee), Ethics Reference: 23/WM/0146, IRAS ID: 328487.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

Funding: INNOVATE UK Smart Grant 10062270
Competing interests:
MS (Chief Investigator), OR-A, KR, LB, MY, EG and JMul have no competing interests
OR-A and KR are employees at Maths in Health BV
PF is an employee of Oxford Pharmagenesis Ltd
DS is the Founder’s Associate at Oto Health Ltd
JMuz is Chief Scientific Officer for Oto Health Ltd
DS and JM have financial interests in Oto Health Ltd
Data availability: At the protocol stage no data have been generated.

Data Availability

No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.